Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 52 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/1/2002 First Published: 8/1/2001


1.		Phase IV Study of Epoetin alfa in Women With Stage I, II, or III Breast Cancer and Chemotherapy-Related Anemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care				Completed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0011004 ORTHO-PR-00-27-012, ORTHO-PR-01-27-003, NCI-G01-2002, NCT00022386


2.		A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care				Completed				18 and over				Pharmaceutical / Industry				CR003541 NCT00216541


3.		A Study of the Management of Blood Loss in Patients Undergoing Surgical Removal of Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care, Treatment				Completed				18 and over				Pharmaceutical / Industry				CR003460 NCT00264095

Last Modified: 5/1/1998


4.		Phase IIIB Open-Label, Controlled, Randomized Study to Identify a Single Subcutaneous Dose of PROCRIT (Epoetin alfa) That Can Be Given Weekly Rather Than the Standard Three-Times-Weekly Dose for the Treatment of Anemia in Cancer Subjects Receiving Platinum-Containing Chemotherapy (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				Pharmaceutical / Industry				RWJPRI-EPO-CA-480 NCI-V96-0978

Last Modified: 12/12/2007 First Published: 1/1/1998


5.		Phase III Randomized Study of Epoetin alfa With or Without Filgrastim (G-CSF) Versus Standard Transfusion Support in Patients With Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				18 and over				NCI				ECOG-1996 E1996, NCT00003138

Last Modified: 2/1/1999 First Published: 4/1/1998


6.		Phase III Randomized Study of Epoetin Alfa versus Placebo in Anemic Patients Receiving Chemotherapy for Stage IV Metastatic Breast Cancer (Summary Last Modified 02/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				18-80				NCI				RPCI-DS-97-10 ORTHO-PR-96-27-004, NCI-G98-1394

Last Modified: 12/5/2002 First Published: 8/1/1998


7.		Phase III Randomized Study of Epoetin Alfa in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Chemotherapy Related Mild or Moderate Anemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				NCI, Pharmaceutical / Industry				MSKCC-97125 ORTHO-PR-96-27-031, RPCI-DS-97-38, NCI-G98-1436, NCT00003341

Last Modified: 5/23/2007 First Published: 12/1/1998


8.		Phase III Randomized Study of Epoetin Alfa in Anemic Patients with Advanced Cancer Undergoing Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				18 and over				NCI				NCCTG-979253 NCI-P98-0133, 97-92-53, NCT00003600

Last Modified: 1/28/2008 First Published: 3/1/2000


9.		Phase III Randomized Study of Radiotherapy With or Without Epoetin alfa in Anemic Patients With Squamous Cell Carcinoma of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Completed				18 and over				NCI				RTOG-9903 RTOG-DEV-1008, NCT00004917, RTOG-99-03

Last Modified: 6/19/2008 First Published: 4/1/2001


10.		Phase III Randomized Study of Adjuvant Cyclophosphamide, Epirubicin, and Fluorouracil Versus Cyclophosphamide, Epirubicin, Filgrastim (G-CSF), and Epoetin Alfa Followed By Paclitaxel Versus Cyclophosphamide and Doxorubicin Followed By Paclitaxel in Premenopausal or Early Postmenopausal Women With Previously Resected Node Positive or High-Risk Node Negative Stage I-IIIB Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				60 and under				Pharmaceutical / Industry				CAN-NCIC-MA21 AMGEN-CAN-NCIC-MA21, NCCTG-CAN-NCIC-MA21, BMS-CAN-NCIC-MA21, JANSSEN-ORTHO-CAN-NCIC-MA21, PFIZER-CAN-NCIC-MA21, NCIC-MA21, NCT00014222, SWOG-CAN-NCIC-MA21, MA21

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute